Bursectomy offers no survival advantage over omentectomy in resectable gastric cancer
Bursectomy offers no survival advantage over non-bursectomy (omentectomy) concluded a phase 3, open-label, randomised controlled trial reported online April 27, 2018 in The Lancet Gastroenterology & Hepatology. As per the researchers, D2 lymph node dissection with omentectomy alone should be done as a standard surgery for resectable cT3–T4a histologically proven gastric adenocarcinoma.
To continue reading this article
Continue reading your article with a Emedinexus account..